US6177242B1 - Genomic DNA fragments containing regulatory and coding sequences for the β2-subunit of the neuronal nicotinic acetylcholine receptor and transgenic animals made using these fragments or mutated fragments - Google Patents

Genomic DNA fragments containing regulatory and coding sequences for the β2-subunit of the neuronal nicotinic acetylcholine receptor and transgenic animals made using these fragments or mutated fragments Download PDF

Info

Publication number
US6177242B1
US6177242B1 US08/358,627 US35862794A US6177242B1 US 6177242 B1 US6177242 B1 US 6177242B1 US 35862794 A US35862794 A US 35862794A US 6177242 B1 US6177242 B1 US 6177242B1
Authority
US
United States
Prior art keywords
dna
nucleotide
sequence
subunit
promoter
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
US08/358,627
Other languages
English (en)
Inventor
Jean-Pierre Changeux
Marina Picciotto
Alain Bessis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut Pasteur de Lille
Original Assignee
Institut Pasteur de Lille
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut Pasteur de Lille filed Critical Institut Pasteur de Lille
Priority to US08/358,627 priority Critical patent/US6177242B1/en
Assigned to INSTITUT PASTEUR reassignment INSTITUT PASTEUR ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: BESSIS, ALAIN, CHANGEUX, JEAN-PIERRE, PICCIOTTO, MARINA
Priority to US08/465,712 priority patent/US6452066B1/en
Priority to CA2165098A priority patent/CA2165098C/en
Priority to AU40373/95A priority patent/AU4037395A/en
Priority to ES95402822T priority patent/ES2238677T3/es
Priority to NZ280674A priority patent/NZ280674A/en
Priority to EP95402822A priority patent/EP0717105B1/en
Priority to DK95402822T priority patent/DK0717105T3/da
Priority to JP32609495A priority patent/JP4450874B2/ja
Priority to PT95402822T priority patent/PT717105E/pt
Priority to AT95402822T priority patent/ATE289628T1/de
Priority to DE69534022T priority patent/DE69534022T2/de
Priority to US09/349,925 priority patent/US6777236B1/en
Priority to US09/552,733 priority patent/US6455754B1/en
Publication of US6177242B1 publication Critical patent/US6177242B1/en
Application granted granted Critical
Priority to US10/843,432 priority patent/US7294463B2/en
Priority to US11/898,925 priority patent/US20090013421A1/en
Priority to JP2007259536A priority patent/JP4468429B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0276—Knock-out vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70571—Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A01K2267/0356—Animal model for processes and diseases of the central nervous system, e.g. stress, learning, schizophrenia, pain, epilepsy
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0393—Animal model comprising a reporter system for screening tests
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination

Definitions

  • This invention relates to DNA and clones of ⁇ 2-subunit of neuronal nicotinic acetylcholine receptor (nAChR) sequences.
  • This invention also relates to genomic DNA fragments containing regulatory and coding sequences for the ⁇ 2-subunit neuronal nAChR and transgenic animals made using these fragments or mutated fragments.
  • the 5′ flanking sequences contain a promoter, which confers neuron-specific expression.
  • the genomic clones demonstrate the importance of the ⁇ 2-subunit gene in the nicotinic system and in the pharmacological response to nicotine.
  • the invention also relates to vectors containing the DNA sequences, cells transformed with the vectors, transgenic animals carrying the sequences, and cell lines derived from these transgenic animals. In addition, the invention describes the uses of all of the above.
  • Neuron-specific expression Many recombinant DNA-based procedures require tissue-specific expression. Unwanted or potentially harmful side-effects of gene transfer therapies and procedures can be reduced through correct tissue-specific expression. Furthermore, the ability to direct the expression of certain proteins to one cell type alone advances the ability of scientists to map, identify or purify these cells for important therapeutic or analytical purposes. Where the cells of interest are neurons or a particular subset of neurons, a need for DNA sequences conferring neuron-specific or subset-specific expression exists.
  • Proteins expressed throughout an organism are often utilized for specific purposes by neurons. By expressing a particular subunit or component of these proteins solely in neuronal tissue, the neuron tailors the protein activity for its purposes. Finding the particular, neuron-specific subunits or components and unraveling why they are produced only in neuronal tissue holds the key to DNA elements conferring neuron-specific expression.
  • the inventors' knowledge of the biology of acetylcholine receptors provided an important foundation for this invention (see Changeux, The New Biologist, vol. 3, no.5, pp. 413-429). Different types of acetylcholine receptors are found in different tissues and respond to different agonists. One type, the nicotinic acetylcholine receptor (nAChR), responds to nicotine. A subgroup of that type is found only in neurons and is called the neuronal nAChR.
  • nAChR nicotinic acetylcholine receptor
  • acetylcholine receptor complex Generally, five subunits make up an acetylcholine receptor complex.
  • the type of subunits in the receptor determines the specificity to agonists. It is the expression pattern of these subunits that controls the localization of particular acetylcholine receptor types to certain cell groups.
  • the genetic mechanisms involved in the acquisition of these specific expression patterns could lead to an ability to control tissue-specific or even a more defined cell group-specific expression.
  • the inventors' work indicates that defined elements in the promoter sequence confer neuron specific expression for the ⁇ 2-subunit.
  • nAChR responds to the agonist nicotine. Nicotine has been implicated in many aspects of behavior including learning and memory (1,2). The pharmacological and behavioral effects of nicotine involve the neuronal nAChRs. Studies using low doses of nicotine (23) or nicotinic agonists (16) suggest that high affinity nAChRs in the brain mediate the effects of nicotine on passive avoidance behavior. Model systems where neuronal nAChR has been altered can therefore provide useful information on the pharmacological effects of nicotine, the role of neuronal nAChR in cognitive processes, nicotine addiction, and dementias involving deficits in the nicotinic system.
  • Functional neuronal nAChRs are pentameric protein complexes containing at least one type of ⁇ -subunit and one type of ⁇ -subunit (3-5) (although the ⁇ 7-subunit can form functional homooligomers in vitro 6,7 ).
  • the ⁇ 2-subunit was selected for this study from among the 7 known ⁇ -subunits and 3 known ⁇ -subunits (3) because of its wide expression in the brain (8-10), and the absence of expression of other ⁇ -subunits in most brain regions (10). Mutation of this subunit should therefore result in significant deficits in the CNS nicotinic system.
  • the inventors have examined the involvement of the ⁇ 2-subunit in pharmacology and behavior. Gene targeting was used to mutate the ⁇ 2-subunit in transgenic mice.
  • mice homozygous for the ⁇ 2-subunit mutation, ⁇ 2 ⁇ / ⁇ .
  • electrophysiological recording from brain slices reveals that thalamic neurons from these mice do not respond to nicotine application.
  • behavioral tests demonstrate that nicotine no longer augments the performance of ⁇ 2 ⁇ / ⁇ mice on the test of passive avoidance, a measure of associative learning. Paradoxically, mutant mice are able to perform better than their non-mutant siblings on this task.
  • ⁇ 2-subunit of the neuronal nAchR we describe a 15 kb fragment of DNA carrying regulatory and coding regions for the ⁇ 2-subunit of the neuronal nAchR.
  • the cell-specific transcription of the ⁇ 2-subunit promoter involves at least two negative regulatory elements including one located in the transcribed sequence.
  • Preferred embodiments of these aspects relate to specific promoter sequences and their use in directing neuron-specific expression in various cells and organisms.
  • An 1163 bp sequence and an 862 bp sequence both confer neuron-specific expression.
  • Other embodiments include the ⁇ 245 to ⁇ 95 sequence of FIG. 1, containing an essential activator element, and the ⁇ 245 to ⁇ 824 sequence of FIG. 1 containing a repressor.
  • a repressor element composed of the NRSE/RE1 sequence is also present in the transcribed region. Certain plasmids comprising these genomic sequences are described as well.
  • the promoter sequences are important for their ability to direct protein, polypeptide or peptide expression in certain defined cells.
  • proteins encoding toxins or the like can be directed to neurons to mimic the degradation of those cells in disease states. Others will be evident from the data described below.
  • the promoters can direct encoded growth factors or oncogenic, tumorigenic, or immortalizing proteins to certain neurons to mimic tumorigenesis. These cells can then be isolated and grown in culture.
  • the promoter sequences can be operatively linked to reporter sequences in order to identify specific neurons in situ or isolate neurons through cell sorting techniques. The isolated, purified neurons can then be used for in vitro biochemical or genetic analysis. Reporter sequences such as LacZ and Luciferase are described below.
  • the inventors provide the genomic clones for mouse ⁇ -2 subunit of the neuronal nAChR. These clones are useful in the analysis of the mammalian nicotinic system and the pharmacology of nicotine.
  • the inventors describe assays using transgenic mice where the genomic clones of the ⁇ 2-subunit have been used to knock out the high affinity binding of nicotine.
  • mutations incorporated into the exons or regulatory sequences for the ⁇ 2-subunit will result in useful mutant transgenic animals.
  • These mutations can be point mutations, deletions or insertions that result in non-efficient activity of the nAChR or even a non-active receptor.
  • methods for determining the ability of a compound to restore or modulate the nAChR activity or function are possible and can be devised. Modulation of function can be provided by either up-regulating or down-regulating receptor number, activity, or other compensating mechanisms.
  • methods to determine the ability of a compound to restore or modulate wild type behavior in the behavioral assays described or known can be devised with the mutant animals.
  • Behavioral assays comprise, but are not limited to, testing of memory, learning, anxiety, locomotor activity, and attention as compared to the untreated animal or patient.
  • Pharmacological assays see 12, 13, 14, 15, 20 to select compounds that restore or modulate nAChR-related activity or behavior can thus be performed with the mutant animals provided by this invention. Dose and quantity of possible therapeutic agents will be determined by well-established techniques. (See, for example, reference 16.)
  • the present model systems comprising transgenic animals or cells derived from these animals can be used to analyze the role of nicotine on learning and behavior, the pharmacology of nicotine, nicotine addiction, and disease states involving deficits in the nicotinic system.
  • potential therapies for nicotine addiction or deficits in the nicotinic system can be tested with the transgenic animals or the cells and cell lines derived from them or any cell line transfected with a DNA fragment or the complete DNA of phage ⁇ 2 (CNCM accession number I-1503).
  • These cell lines would include all those obtained directly from homozygous or heterozygous transgenic animals that carry or are mutated in the ⁇ 2-subunit sequences.
  • this would include cell lines created in culture using natural ⁇ 2-subunit sequences or mutated ⁇ 2-subunit sequences. Techniques used could be, for example, those cited in PCT WO 90/11354.
  • Dementias such as Alzheimer's disease, in which the high affinity nicotine binding site are diminished suggest that the present model can be used to screen drugs for compensation of this deficit. Accordingly, methods for screening compounds for the ability to restore or detectably effect activity of the neuronal nicotinic acetylcholine receptor comprising adding the compound to an appropriate cell line or introducing the compound into a transgenic animal can be devised. Transgenic animals and cell lines generated from this invention can be used in these methods. Such animal or cell line systems can also be used to select compounds which could be able to restore or to modulate the activity of the ⁇ 2 gene.
  • the transgenic animals obtained with the ⁇ 2-subunit gene sequence can be used to generate double transgenic animals.
  • the ⁇ 2-subunit transgenic animal can be mated with other transgenic animals of the same species or with naturally occurring mutant animals of the same species.
  • the resulting double transgenic animal, or cells derived from it, can be used in the same applications as the parent ⁇ 2-subunit transgenic animal.
  • Both the promoter sequences and the genomic clones can be used to assay for the presence or absence of regulator proteins.
  • the gel shift assays below exemplify such a use.
  • the sequences or clones can also be used as probes by incorporating or linking markers such as radionuclides, fluorescent compounds, or cross-linking proteins or compounds such as avidin-biotin. These probes can be used to identify or assay proteins, nucleic acids or other compounds involved in neuron action or the acetylcholine receptor system.
  • mutate or modify nucleic acid sequences can be used in conjunction with this invention to generate useful ⁇ 2 mutant animals, cell lines, or sequences.
  • Such methods include, but are not limited to, point mutations, site-directed mutagenesis, deletion mutations, insertion mutations, mutations obtainable from homologous recombination, and mutations obtainable from chemical or radiation treatment of DNA or cells bearing the DNA.
  • DNA sequencing is used to determine the mutation generated if desired or necessary.
  • the mutant animals, cell lines or sequences are then used in the DNA sequences, systems, assays, methods or processes the inventors describe.
  • the mutated DNA will, by definition, be different, or not identical to the genomic DNA.
  • Mutant animals are also created by mating a first transgenic animal containing the sequences described here or made available by this invention, with a second animal.
  • the second animal can contain DNA that differs from the DNA contained in the first animal. In such a way, various lines of mutant animals can be created.
  • recombinant DNA techniques are available to mutate the DNA sequences described here, as above, link these DNA sequences to expression vectors, and express the ⁇ 2-subunit protein or mutant derived from the ⁇ 2-subunit sequences.
  • the ⁇ 2-subunit or mutant can thus be analyzed for biochemical or behavioral activity.
  • mutated DNA sequences can be generated that prevent the expression of an efficient nAchR.
  • the promoter sequences described can be used in expression vectors or systems to drive expression of other proteins.
  • Obtainable DNA sequence can thus be linked to the promoter or regulatory sequences the inventors describe in order to transcribe those DNA sequences or produce protein, polypeptide, or peptides encoded by those DNA sequences.
  • nAchR ⁇ 2-subunit transcripts are only detected in the Spiriformis lateralis nucleus in the chick diencephalon (Daubas et al., 1990) or the Interpeduncularis nucleus in the rat (Wada et al., 1988). Also the ⁇ 3, ⁇ 4 and ⁇ 3-subunit transcripts are only detected in a small set of structures in vertebrate brain (references in Zoli et al., 1994).
  • nAchR, ⁇ 4, ⁇ 5, ⁇ 7, and ⁇ 2-subunit gene transcripts show a much wider distribution.
  • the ⁇ 2-subunit transcripts are found in the majority of neurons in the CNS and in all the peripheral neurons that express the nAchR (Role, 1992; Hill et al., 1993).
  • nAchR species a wide diversity of nAchR species occurs in vertebrates.
  • Each species has a defined pattern of expression involving diverse categories or groups of neurons.
  • the neurons from medial Habenula interconnect with those from the Interpeduncularis nucleus and yet each express distinct sets of nAchR subunits (see Role, 1992 for review) exhibiting different physiological and pharmacological profiles (Mulle et al., 1991).
  • the transcription start sites that we have characterized are located downstream from the position of the longest rat (Deneris et al., 1988) and human (Anand and Lindstrom, 1990) ⁇ 2 cDNA 5′ end (see FIG. 1 ). This implies that in human and rat, another transcription start site is used.
  • Such a discrepancy between species has already been demonstrated for the ⁇ -subunit of the muscle nAchR (D ⁇ umlaut over (u) ⁇ rr et al., 1994, see also Dong et al., 1993; Toussaint et al., 1994).
  • the ⁇ 2 subunit gene Bessis et al., 1993
  • no upstream exon could be detected.
  • the promoter region is located between the Eco47III located in exon 1 (see FIG. 1) (SEQ ID NO:22) and the BamHI site 4.5 kb upstream.
  • One preferred embodiment is the 1163 bp sequence described in FIG. 1 between the EcoRI and Eco47III sites.
  • Regulatory sequences may be located in the 2 kb downstream from the Eco47III site.
  • the regulatory elements from the nAchR ⁇ 2-subunit sequences can be used to direct the neuron specific expression of a nucleotide sequence encoding a protein, polypeptide or peptide linked to them.
  • Said protein, polypeptide, or peptide can be toxins, trophic factors, neuropeptides, tumorigenic, oncogenic, or immortalizing proteins, or any other protein that can change the function of the neuron.
  • the 1163 bp promoter contains regulatory sequences for both tissue-specific and temporal specific transcription of the ⁇ 2-subunit gene. Transient transfection experiments showed that the 1163 bp fragment contains sufficient information to confer cell-specific expression of the nAchR ⁇ 2-subunit gene. We showed that the same promoter directs a strict cell-specific transcription of the ⁇ -galactosidase ( ⁇ -gal) reporter gene. Moreover, the transgenic construct appears to be activated with the same timing as the endogenous ⁇ 2-subunit gene during the development of the early embryonic nervous system (Zoli et al., 1994). At later stages of development, most of the peripheral ⁇ 2 expressing neurons are still labelled (FIGS. 4C, D).
  • the promoter sequence was tested in transgenic mice by generating two lines (13 and 26) expressing ⁇ -gal under the control of the ⁇ 2-subunit promoter. In CNS, the pattern of ⁇ -galactosidase expression is different between the two lines. Only a subset of the cells that normally express ⁇ 2 express the transgene. This type of discrepancy between the expression of the transgene and the endogenous gene has already been described for the dopamine ⁇ -hydroxylase gene promoter (Mercer et al., 1991; Hoyle et al., 1994) or for the GAP-43 gene (Vanselow et al., 1994). Unexpected expression has been observed in transgenic line 13 in the genital tubercule and in skin muscles.
  • TrkA the high affinity nerve growth factor receptor
  • p 75 the low affinity nerve growth factor receptor
  • p 75 expression (like the expression of the ⁇ 2-promoter transgene) is transient in many peripheral ganglia and brain nuclei, decreasing to undetectable levels at perinatal or early postnatal ages. It is therefore possible that the ⁇ 2-subunit promoter contains an element controlled by the activation of p 75 , or that both the ⁇ 2 transgene and p 75 gene are controlled by a common regulator.
  • the promoter seems to lack some regulatory elements active in the brain, the existing regulatory elements are sufficient to allow a cell- and development-specific expression of ⁇ -galactosidase in the PNS, in the spinal cord, and in several brain structures.
  • the promoter can also be used in assays to identify regulator proteins in neuronal tissue.
  • An NRSE/RE1 element is located at the 3′ extremity of the promoter. This element has already been shown to restrict the activity of promoters in neuronal cells (Kraner et al., 1992; Mori et al., 1992; Li et al., 1993). In the 1163 bp promoter of the ⁇ 2-subunit gene, point mutation of this sequence leads to a ⁇ 100 fold increase of the transcriptional activity in fibroblasts implying that this sequence is involved in the neuron-specific expression of the ⁇ 2-subunit gene.
  • sequence comparison shows that this sequence is highly conserved in rat and human ⁇ 2-subunit cDNAs (Deneris et al., 1988; Anand and Lindstrom, 1990) as well as in several promoters of genes expressed in the nervous system, such as the middle-weight neurofilament gene, the CAM-L1 gene, the Calbinbin gene, or the cerebellar Ca-binding protein gene (see Table 1B).
  • FIG. 6 Deletion experiments described in FIG. 6 show that an essential activator element is present between nucleotides ⁇ 245 and ⁇ 95. An Sp1 binding site and an E-box could be detected in this region. Sp1 sites are ubiquitous factors, whereas E-boxes have been involved in several genetic regulatory mechanisms in muscle (see Bessereau et al., 1994 for the nAchR ⁇ 1-subunit) as well as in neurons (Guillemot et al., 1993).
  • Dyad elements have also been reported in some neuronal promoters, such as those of the Tyrosine hydroxylase gene (Yoon and Chikaraishi, 1994), the SCG1O gene (Mori et al., 1990), the GAP43 gene (Nedivi et al., 1992), or in the flanking region of the N-CAM gene (Chen et al., 1990).
  • Results shown in Table 1A demonstrate that in neuroblastomas, the 1163 bp promoter mutated in the E-box/Dyad is significantly less active than the wild type promoter.
  • a gel shift assay (FIG. 7) further demonstrates that the E-box/Dyad is able to bind specific complexes.
  • E-Box/Dyad is responsible for at least part of the activation of ⁇ 2-subunit gene transcription.
  • transactivation experiments of heterologous promoters suggest that the E-box cooperates with the Sp1 site located 27 bp upstream to positively activate transcription. This type of cooperation between an E-Box and an Sp1 binding site has already been demonstrated for the regulation of the muscle nAchR ⁇ 1-subunit transcription (Bessereau et al., 1993).
  • the ⁇ 2-subunit gene is primarily regulated by negatively acting elements and by one positive element that comprises an E-box. This double regulation seems to be a general feature shared by several neuronal genes (Mandel and Mckinnon, 1993) and allows fine tuning of the transcription of neuronal genes. Moreover, our transgenic studies show that the 1163 bp promoter confers a tight neuron-specific expression, but lacks some developmental or CNS-specific regulatory elements.
  • FIG. 1 Nucleotide sequence of the region surrounding the initiator ATG of the ⁇ 2-subunit gene.
  • the four vertical arrowheads show the four extremities found using RACE-PCR and SLIC, corresponding to the transcription start sites.
  • the vertical arrows indicate the position corresponding to the 5′ end of the longest rat (r) and human (h) ⁇ 2-subunit cDNA clones (Deneris et al., 1988).
  • the endpoints of the deletions used in the experiments described in FIG. 3 are indicated above the sequence. Nucleotides located in the intron are typed in lower cases.
  • FIGS. 2 (A-B): Mapping of the 5′ end of the ⁇ 2-subunit mRNA.
  • RNA from DBA2 mouse brain (5 and 15 ⁇ g, lane 2 and 3 respectively) and yeast tRNA (15 ⁇ g, lane 1 ) were hybridized to a 32 P-labeled RNA probe containing 158 nucleotides of intron 1, and 789 nucleotides of upstream sequences ( ⁇ 634/+155).
  • the size of the protected bands were estimated according to the lower mobility in acrylamide of RNA as compared to DNA (Ausubel et al., 1994) and by comparison with the sequence of M13mp18 primed with the universal primer.
  • the arrow on the left part of the gel points to the major protected band.
  • FIG. 3 Cell-specific expression of the ⁇ 2-subunit promoter in vitro.
  • luciferase activity of the plasmids were normalized to the activity of the promoterless plasmid (KS-Luci, described in Materials and Methods).
  • RACE-PCR on mRNA extracted from SK-N-Be transfected with EE1.2-Luci, using luciferase oligonucleotides (described in Material and Methods) showed that the amplified fragment had the expected size for the correct transcription initiation site.
  • FIG. 6 Expression of the Luciferase fusion genes containing 5′ end deletions of the ⁇ -subunit promoter.
  • Plasmids are called nnnE-Luci, where nnn is the size in nucleotides of the insertion, and E is the 5′ end restriction site (Eco47III). The arrow indicates the transcription start site.
  • the activities of EE1.2-Luci are from FIG. 3 .
  • FIG. 7 Gel shift experiment. Autoradiogram of the mobility shift experiment.
  • the probe used was a 32 P labelled double stranded E-D oligonucleotide. This oligonucleotide carries only the E-Box/Dyad element, whereas the oligonucleotide S-E carries the Sp1 binding site as well as the E-Box/Dyad element.
  • the competitor oligonucleotides were used in 10- and 100-fold molar excess, except for S-E that was used only in 100-fold molar excess.
  • a-i Normal genomic structure of the mouse ⁇ 2-subunit gene. Portion of exon one removed by the recombination event is shaded in light grey. ATG-initiator methionine. Boxes represent exons I-IV.
  • a-ii Targeting replacement vector used to disrupt the endogenous ⁇ 2-subunit gene. Initiator methionine and the rest of the first exon were replaced with the coding region of NLS-lacZ and the MCl neo R expression cassette 25 .
  • the construct was able to direct lacZ expression after stable transfection of PC12 cells (not shown), but lacZ expression was never detected in recombinant animals, despite the lack of obvious recombination in the lacZ DNA.
  • Diphtheria toxin-A gene (DTA) 26 was used to select against random integration.
  • a-iii Structure of the mutated ⁇ 2-gene. Restriction sites: H, HindIII; R, EcoRI; E, Eco47III; P, PstI.
  • Black arrows primers used to detect recombination events in embryonic stem (ES) cells.
  • Grey arrows primers used to detect the wildtype or mutated ⁇ 2 genes.
  • b PCR analysis of tail DNA from a +/+, +/ ⁇ and a ⁇ / ⁇ mouse.
  • c Southern blot analysis of tail DNA restricted with HindIII from the same mice analyzed in panel b.
  • d Western blot analysis of total brain protein using a monoclonal antibody raised against the ⁇ 2-subunit.
  • the ⁇ 2-targeting vector was constructed by inserting a multiple cloning site (MCS) into the MCl neo cassette (GTC GAC GGT ACC GCC CGG GCA GGC CTG CTA GCT TAA TTA AGC GGC CGC CTC GAG GGG CCC ATG CAT GGA TCC (SEQ ID NO:30)).
  • MCS multiple cloning site
  • GTC GAC GGT ACC GCC CGG GCA GGC CTG CTA GCT TAA TTA AGC GGC CGC CTC GAG GGG CCC ATG CAT GGA TCC (SEQ ID NO:30) A 4.1 kB EcoRI-Eco47III ⁇ 2-genomic fragment 5′ to the ATG and a 1.5 kB PstI ⁇ 2-genomic fragment starting within the first intron of the ⁇ 2-gene were cloned into the MCS.
  • HMl 27,28 embryonic stem cells (5 ⁇ 10 ) were transfected with the linearized targeting vector by electroporation as described 25 . Twenty-four surviving G418-resistant clones were screened by PCR ⁇ 2-primer-GCC CAG ACA TAG GTC ACA TGA TGG T (SEQ ID NO:31); neo-primer-GTT TAT TGC AGC TTA TAA TGG TTA CA (SEQ ID NO:32)). Four were positive and were later confirmed by Southern blot analysis. Clones were injected into 3.5-day-old blastocysts from non-agouti, C57BL/6 mice and planted in receptive females.
  • mice All resulting male chimaeric mice were mated to F1, C57BL/6xDBA/2 non-agouti females. Of 15 chimaeras, one showed germ-line transmission. ⁇ 2 +/ ⁇ heterozygotes were mated and offspring were evaluated by PCR analysis (panel b). b, PCR was 35 cycles of 94°/1 min, 65°/2 min and 72°/1 min. c, Southern blotting was performed as described 29 . The 1.5 kB PstI genomic fragment used for the targeting construct was labelled by random priming. d, Western blotting was performed as described 29 using monoclonal antibody 270 11 .
  • FIGS. 9 Mapping of the neuronal nAChR in mouse brain using in situ hybridization and tritiated nicotine binding.
  • A In situ hybridization using antisense oligonucleotide probes based on the sequence of the cDNAs encoding the ⁇ 2-, ⁇ 4- and ⁇ 4-subunits of the nAChR to detect their respective mRNAs in serial sections from the brains of ⁇ 2 +/+, +/ ⁇ and ⁇ / ⁇ mice. Midthalamic sections are shown.
  • White arrows indicate the MHb labelled by the ⁇ 4-antisense oligonucleotide.
  • EDTA ethylenediaminetetraacetic acid
  • 0.1 mg/ml polyA Boehringer
  • 0.5 mg/mlyeast RNA Sigma
  • 0.05 mg/ml herring sperm DNA Promega
  • Probes were applied at a concentration of 2000-3000 Bcq/30 ⁇ l section (corresponding to around 15 fmol/section). After removal of coverslips and initial rinse in 2 ⁇ standard saline citrate (SSC) solution (3M NaC1/0.3M sodium citrate) at room temperature (two time for 5 min.), sections were washed four times for 15 min in 2 ⁇ SSC/50% formamide at 42° C. and, then, two times for 30 min in 1 ⁇ SSC at room temperature. 1 mM dithiothreitol was added to all washing solutions. After rinsing in ice-cold distilled water and drying, they were exposed for 10-20 days to Hyperfilm ⁇ max (Amersham) and then to a photographic emulsion (NTB2, Kodak) for 1-2 months.
  • SSC standard saline citrate
  • a score from 1+ (low intensity) to 3+ (high intensity) was assigned to the labelling of the anatomical structures based on the subjective evaluation of two experimenters.
  • Background labelling was considered the density of grains in nonneural tissues high cellularity (such as the liver and muscles) or with high density of extracellular matrix (such as cartilage) or the density of labelling over neural structures after displacement with 20 ⁇ cold probe.
  • the scores must be regarded with caution. For instance, decreases in labelling intensity of a developing structure may be due to dispersion of positive cells in the structure caused by multiplication of negative cells or formation of neuronal processes.
  • oligonucleotides had the same length and they were labelled according to the same protocol, no attempt to compare the signal intensity or different transcripts was made. Unless specified otherwise, the labeling shown in the pictures has been obtained by using oligonucleotides no. 31 ( ⁇ 3), 47 ( ⁇ 4), 51 (12), and 62 ( ⁇ 4) (see Table 1 for oligonucleotide characteristics). Specificity controls. For each mRNA, two to four oligonucleotides were selected in unique parts of the sequence (e.g., the putative cytoplasmic loop between M3 and M4 for nAChR subunits). An initial assessment of the specificity was performed by searching for possible homology with other known sequences in Genbank/EMBL.
  • oligonucleotide probes used fulfilled all these criteria, with the exception of the four probes against ⁇ 3 mRNA, which did not satisfy criterion 2.
  • Previous studies based on cRNA probes showed a relatively widespread distribution of this subunit mRNA in adult rats, notably high levels in the cerebral cortex layer IV, entorhinal cortex layer II, anterior and ventral thalamic nuclei, medial and lateral geniculate nuclei, medial habenula, posterior hypothalamus and supramammillary nuclei, pineal gland, motor nuclei of the V and VII nerves, locus coeruleus, nucleus ambiguus, and area postrema (Wada et al. 1989).
  • Oligonucleotides ⁇ 2: (SEQ ID NO:1) 5′-TCG CAT GTG GTC CGC AAT GAA GCG TAC GCC ATC CAC TGC TTC CCG-3′; ⁇ 4 (SEQ ID NO:2): 5′-CCT TCT CAA CCT CTG ATG TCT TCA AGT CAG GGA CCT CAA GGG GGG-3′; ⁇ 4 (SEQ ID NO:3): 5′-ACC AGG CTG ACT TCA AGA CCG GGA CGC TTC ATG AAG AGG AAG GTG-3′. B, 3 H-nicotine binding was performed as described by Clarke et al 30 . Fourteen ⁇ m coronal sections were incubated at room temperature for 30 min.
  • FIGS. 10 Patch clamp recording of nicotine evoked currents in the MHb and anterior thalamus of ⁇ 2 +/+ and +/+mice.
  • A Representative recordings from cells in the MHb and the anterior thalamus of wildtype and ⁇ 2 ⁇ / ⁇ mice. The off-rate of the agonist is significantly greater in the MHb than in the anterior thalamus, resulting in a different kinetics of response in the two structures.
  • the response to nicotinic agonists of the MHb is maintained in ⁇ 2 ⁇ / ⁇ animals, while the response to nicotinic agonists of the anterior thalamus is completely abolished in ⁇ 2 ⁇ / ⁇ mice.
  • B table of responses to nicotinic agonists in various nuclei of ⁇ 2 +/+ and ⁇ / ⁇ mice.
  • Coronal slices were obtained from the thalamus of 8-12 day old mice using a Dosaka slicer in ice cold ACSF medium (125 mM NaCl/26 mM NaHCO 3 /25 mM Glucose/1.25 mM NaH 2 PO 4 /2.5 mM KCl 2.5/2 mM CaCl 2 /1 mM MgCl 2 pH 7.3). Slices were maintained in the same medium for 1-8 hours. Cells in slices were visualized through a Zeiss microscope.
  • FIGS. 11 Performance of ⁇ 2 ⁇ / ⁇ mice and their wildtype siblings on the passive avoidance test.
  • A response to various levels of footshock in retention test following a post-training injection of either vehicle or nicotine (10 ⁇ g/kg). Average step-through latency during the training trial was 17.0+/ ⁇ 3.6 sec for mutant mice and 15.0+/ ⁇ 3.5 sec for their nonmutant siblings.
  • B bar graph showing the difference in retention latency between wildtype and homozygous ⁇ 2 mutant mice injected with either vehicle or nicotine (10 ⁇ g/kg) at foot shock intensity of 2.00 mAmp. Data are represented as means +/ ⁇ S.E.M.
  • FIG. 12 Phage and plasmids containing all or part of the ⁇ 2-subunit gene and the promoter.
  • the numerals indicate the size of the fragment and the letters indicate the restriction sites used to generate it.
  • FIG. 1 shows the nucleotide sequence of 1.2 kb upstream from the initiator ATG.
  • Hybridization conditions can be modified by known techniques 29 to determine stringent conditions for this probe. Changes in the hybridization conditions such as temperature (from about 45° C. to about 65° C.) and SSC buffer concentration (from about 0.1 ⁇ SSC to about 6 ⁇ SSC), as well as changes in the temperature of and the buffer for the washing conditions can be made to develop sufficiently stringent conditions that allow hybridization to the ⁇ 2-subunit sequences. Other related sequences can thus be isolated from other libraries based on this hybridization procedure. Human sequences will be isolated by using hybridization conditions such as 45° C. and 6 ⁇ SSC.
  • a phage, ⁇ 2 nAchR is deposited under the accession number I-1503. This phage contains 15-20 kb of genomic DNA including the promoter sequences and the coding sequences for all of the exons of the murine ⁇ 2-subunit of neuronal nAchR. Two E.coli cultures bearing plasmids have also been deposited. Plasmid pSA9 in E.
  • coli DH5 ⁇ has accession number I-1501 and contains 9 kb of murine genomic DNA including the regulatory sequences and regions coding for exons 1, 2 and 3 of the ⁇ 2-subunit.
  • Plasmid pEA5 in E. coli DH5 ⁇ has accession number I-1502 and contains 5 kb of murine genomic DNA including a region of about 1.2 kb upstream of the Eco47-III site and a region coding for exons 1 to 5 of the ⁇ 2-subunit.
  • the inventors intend to deposit the nucleotide sequence data reported here in the EMBL, GenBank and DDBJ Nucleotide Sequence Databases under the accession number: X82655.
  • RNA mapping we used different batches of total RNA extracted from DBA2 embryos at stage E13 or E15. The RNA samples were first digested with DNase I to avoid DNA contamination.
  • RACE-PCR (Frohman et al., 1988).
  • the mRNA was hybridized 5 minutes at 80° C. with 10 pmol of primer.
  • the synthesis of the cDNA was performed using 400 u MMLV (Gibco) for 45 minutes at 37° C. in the buffer recommended by the supplier. After a phenol/chloroform extraction, the cDNA was ethanol precipitated.
  • the terminal transferase reaction was performed in 0.2 M potassium cacodylate; 25 mM Tris-HCl pH 6.6; 25 mg/ml BSA; 1.5 mMCoCl 2 ; 50 nM DATP and 50 u Terminal transferase (Boehringer) for 30 minutes at 37° C..
  • one tenth of the terminal transferase reaction was amplified using Promega's Taq DNA polymerase (30 cycles, 1 minute at: 94° C.; 55° C.; 72° C.). The amplified fragment was then loaded on an agarose gel. The gel was blotted and hybridized to oligonucleotide p2.
  • pEx2 as a primer for cDNA synthesis
  • p0/BEpT for PCR to map mRNA from brain.
  • OLUCI3 synthesis of cDNA
  • OLUCI2/BEpT PCR
  • the cDNA was first synthesized from 5 ⁇ g total RNA using pEx3 (6 pmol) as a primer in 50 mM Tris-HCl pH 8.3; 8 mM KCl; 1.6 mM MgCl 2 ; 5 mM spermidine; 0.5 mM dNTP; 1 u/ ⁇ l RNasin; 0.1 mg/ml BSA; 70 mM ⁇ -mercaptoethanol; 80 u AMV reverse transcriptase (Promega) at 42° for 45 minutes. The RNA was subsequently degraded in NaOH.
  • the first strand of the cDNA was then ligated with the oligonucleotide A5′.
  • the resulting single stranded cDNA was then submitted to two rounds of PCR amplification with oligonucleotides A5′-1/p0 and A5′-2/pl (35 cycles 94° C. 1 minute; 60° C. 30 seconds; 72° C. 45 seconds).
  • oligonucleotides were the following:
  • A5′ (SEQ ID NO:4): 5′-CTGCATCTATCTAATGCTCCTCTCGCTACCTGCTCACTCTGCGTGACATC
  • A5′-1 (SEQ ID NO:5): 5′-GATGTCACGCAGAGTGAGCAGGTAG
  • A5′-2 (SEQ ID NO:6): 5′-AGAGTGAGCAGGTAGCGAGAGGAG
  • pEx2 (SEQ ID NO:10): 5′-GCCGCTCCTCTGTGTCAGTACCCAAAACCC
  • BEpT SEQ ID NO:12: 5-GCGGGATCCGAATTC(T) 21 A/C/G
  • OLUCI3 (SEQ ID NO:13): 5′-CGAAGTATTCCGCGTACGTGATG
  • OLUCI2 (SEQ ID NO:14): 5′-ACCAGGGCGTATCTCTTCATAGC
  • KS-Luci The HindIII/KpnI restriction fragment of the pSVOAL plasmid (de Wet et al., 1987) was subcloned in the corresponding site of Bluescript KS. The most 5′ EcoRI/BsmI (45 bp) fragment of the Luciferase gene was then deleted according to (de Wet et al., 1987) and replaced by a Sal I site. The 342 bp PvuII/HindIII restriction fragment of SV40 containing the polyadenylation sites was subsequently subcloned into the EagI sites using adaptors.
  • EE1.2-Luci The 1.2 kbp EcoRI/Eco47II fragment of the ⁇ 2 phage was inserted in the EagI/SaII sites of KS-Luci using adaptors. The 5′ end deletions of the promoter were obtained using Bal3.1 exonuclease as in Current Protocols in Molecular Biology (Ausubel, et al., 1994).
  • the mutations were introduced using the Sculptor kit (Amersham).
  • the mutated sequence was: +24 (SEQ ID NO:15) ACCAC TT ACA instead of (SEQ ID NO:16) ACCAC GG ACA, as this mutation was shown to reduce the activity of the NRSE element (Mori et al., 1992).
  • the mutated sequence was: ⁇ 120 (SEQ ID NO:17) TC CT CA GG instead of (SEQ ID NO:18) TC CA CT TG .
  • FIG. 7 shows that a nuclear protein is able to bind to the wild type sequence, but not to the mutated sequence.
  • Neuroblastomas N1E115, human SK-N-Be, HeLa and 3T6 fibroblasts, 293 Human kidney cells and SVLT striatal cells (Evrard et al., 1990) were grown in DMEM+10% FCS supplemented with 1% glutamine and 1% streptomycin.
  • PC12 cells were grown in DMEM+10% HS+5% FCS supplemented with 1% glutamine and 1% streptomycin.
  • Cells were plated at 10 5 to 4 ⁇ 10 5 cells/60 mm 2 plates. The next day cells were transfected in 750 ⁇ l of DMEM+2% Penicillin/Streptomycin for 5 to 12 hours with 1 ⁇ g DNA mixed with 2.5 ⁇ l of Transfectam (IBF/Sepracor) in 150 mM NaCl. The Luciferase activity was measured 48 hours later. DNA was prepared using Qiagen or Wizard prep (Promega) kits. When plasmid activities were compared, all plasmids were prepared the same day. At least two different DNA preparations were tested for each plasmid. All transfections were done in duplicate and repeated at least three times.
  • the luciferase gene from EE1.2-Luci was excised and replaced by the nlsLacZ gene (Kalderon et al., 1984).
  • the ⁇ 2-promoter/nlsLacZ fragment was electroeluted from a TAE agarose gel then further purified by ethanol precipitation, and finally resuspended in Tris-HCl 10 mM pH 7.5; EDTA 0.1 mM.
  • the DNA solution (3 ng/ml) was injected into fertilized oocytes of C57BL6xSJL hybrids. Staining of tissues was performed as described in Mercer et al., 1991.
  • Oligonucleotides were labeled either with ⁇ [ 32 P]ATP and T4 polynucleotide kinase, or with ⁇ [ 32 P]CTP and Klenow enzyme as in Current Protocols in Molecular Biology. Nuclear extracts were prepared from ⁇ 10 7 cells as described (Bessis et al., 1993).
  • oligonucleotide For binding, 1 nmol of labeled oligonucleotide was mixed with 0,5 ⁇ g of protein extract in 10 mM Hepes pH 8, 10% glycero], 0,1 mM EDTA, 0.1 M NaCl, 2 mM DTT, 0.1 mg/ml BSA, 4 mM MgCl 2 , 4 mM spermidine, 1 mM PMSF, 1 ⁇ g polydIdC in 20 ⁇ l. The reaction was incubated for 10 minutes on ice. The DNA-protein complexes were then analyzed on a 7% polyacrylamide gel.
  • oligonucleotides used in this experiments were double stranded with the following sequences (the underlined nucleotides are changed between the mutated and the wild type oligonucleotides):
  • E-D (SEQ ID NO:19) 5′-TCCTCCCCTAGTAGTTCC A C TT GTGTTCCCTAG
  • S-E (SEQ ID NO:21) 5′-CTAGCTCCGGGGCGGAGACTCCTCCCC TAGTAGTTCCACTTGTGTTCCCTAG
  • FIG. 1 A ⁇ phage containing the gene encoding the ⁇ 2-subunit was cloned and a region surrounding the initiator ATG was sequenced (FIG. 1 ).
  • the transcription initiation site was first mapped by RNase protection (FIG. 2 A). This method allowed us to detect at least three initiation sites. However, minor additional start sites might not have been detected in these experiments.
  • the size of the main protected band was estimated at about 150 nucleotides.
  • FIG. 1 Analysis of the sequence of the flanking region revealed several consensus DNA binding elements: an Sp1 site ( ⁇ 146), a cAMP responsive element binding (CREB) site ( ⁇ 287; Sassone-Corsi, 1988), a nuclear receptor response element ( ⁇ 344 to ⁇ 356; Parker, 1993), a GATA-3 site ( ⁇ 1073; Ko and Engel, 1993), and a weakly degenerate Octamer motif ( ⁇ 522). Moreover, an E-box ( ⁇ 118) contained in a dyad symmetrical element could be recognized.
  • CREB cAMP responsive element binding
  • the proximal region ( ⁇ 245 to +82) also has an unusually high GC content (67%) and a high number of dinucleotide CpG that may have some regulatory significance (Antequera and Bird, 1993).
  • a 20 bp sequence identical to the NRSE (Neural Restrictive Silencer Element; Mori et al., 1992) or RE1 (Restrictive Element; Kraner et al., 1992) sequence was found in the 3′ end of the 1.2 kbp fragment (+18 to +38).
  • a construct was generated containing the 1163 bp EcoRI/Eco47III fragment (from ⁇ 1125 to +38) of the ⁇ 2-subunit 5′ flanking region fused to the Luciferase gene (de Wet et al., 1987) (plasmid EE1.2-Luci).
  • the polyadenylation sites of SV40 were inserted upstream from the ⁇ 2-subunit sequences to avoid readthrough.
  • the transcriptional activity of the plasmid EE1.2-Luci was then tested by transient transfection into pheochromocytoma (PC12) cells, neuroblastoma cell lines NIE 115 and SK-N-Be, SVLT, a striatal cell line (Evrard et al., 1990), NIH3T6 or HeLa fibroblasts and human kidney cell line 293.
  • PC12 pheochromocytoma
  • the 1.2 kbp fragment is 20 to 180-fold more active in mediating transcription of the reporter gene than in the other cell lines.
  • the transcriptional activity of the 1.2 kbp fragment is not significantly higher than that of the promoterless vector (FIG. 3 ). Therefore, the ⁇ 2-subunit promoter is not active in these cell lines.
  • the EcoRI/Eco47III fragment was linked upstream from the nls- ⁇ -galactosidase reporter gene (Kalderon et al., 1984).
  • the polyadenylation signals from SV40 were ligated downstream of the coding sequences.
  • the resulting 4.7 kb fragment was subsequently microinjected into the male pronuclei of fertilized eggs from F1 hybrid mice (C57B16xSJL). DNA extracted from the tails of the offspring was analyzed for the presence of the ⁇ -galactosidase gene by the polymerase chain reaction (PCR).
  • PCR polymerase chain reaction
  • the expression of the transgene could be detected in the peripheral ganglia in E10.5 and E11 embryos.
  • the labelling was examined in E13 total embryos (FIG. 4A) and in brains at later ages (E17, PO and adulthood).
  • E13 labelling was prominent in PNS: strong labelling was observed in the dorsal root ganglia (DRG, FIGS. 4 and 5 C, D); some ganglia associated with the cranial nerves (the trigeminal see FIG. 5A, geniculate, glossopharyngeal and vagal ganglia); the ganglia of the sympathetic chain (FIG. 5C, D); the ganglionic cells of the retina (FIG.
  • the dispersed cells of the V mesencephalic nucleus appeared strongly stained, as well as the pontine nuclei, the prepositus hypoglossal nucleus and a few dispersed cells in the pontine tegmentum.
  • the luciferase activity did not significantly change in neuroblastomas but increased in fibroblasts (FIG. 6 ).
  • the activity of the remaining promoter continued to increase in the fibroblasts but not in neuroblastomas (see plasmid 862E-Luci, FIG. 6 ).
  • the 157 and 301 bp deleted plasmids carry repressor elements which are only active in fibroblasts.
  • the truncated 862 bp promoter still displayed a neuron-specific activity (FIG.
  • the 3′ end of the ⁇ 2-subunit promoter contains putative protein factor binding sites.
  • the E-box located at nt-118 was a good candidate, we analyzed the effect of mutations in this element on transcriptional activity.
  • Table 1A shows a 40%. reduction of the transcriptional activity of the mutated promoter compared to that of the wild type promoter. The role of the E-box in non-neuronal tissues was more difficult to assess as the basal level of transcription was already low in fibroblasts.
  • NRSE/RE1 sequence is also present in the proximal region and has been shown to act as a silencer in fibroblasts but not in PC12 cells or neuroblastomas (Kraner et al., 1992; Li et al., 1993; Mori et al., 1992). Point mutation of this sequence in the context of the 1163 bp promoter resulted in a 105-fold increase in the transcriptional activity in fibroblasts, and only a 3-fold increase in neuroblastomas (Table 1A). This sequence is thus responsible for at least part of the cell-specific expression of the ⁇ 2 subunit gene.
  • FIG. 8 The ⁇ 2-subunit of the nAChR was disrupted in embryonic stem (ES) cells, and mice deficient in this subunit were subsequently generated (FIG. 8 ). ⁇ 2 ⁇ / ⁇ mice were viable, mated normally and showed no obvious physical deficits. Overall brain size and organization were normal (see for example FIGS. 9, A and B). Western blot analysis of total brain homogenates using anti- ⁇ 2 monoclonal 270 11 (FIG. 8 d ) and immunocytochemistry throughout the brain using a polyclonal anti- ⁇ 2 antibody 9 demonstrated that the immunoreactivity detected in control mice was absent in ⁇ 2 ⁇ / ⁇ mice and was diminished in ⁇ +/ ⁇ mice. ⁇ 2-encoding mRNA was undetectable in ⁇ 2 ⁇ / ⁇ mice by in situ hybridization using ⁇ 2-antisense oligonucleotides (FIG. 9 A).
  • ⁇ 4- and ⁇ 2-subunits largely overlap in the brain, and these subunits are thought to combine to form the predominant nAChR isoform in the CNS 12 .
  • ⁇ 4- is the only subunit identified thus far that might also be able to form functional heteropentamers with the ⁇ 4-subunit.
  • the ⁇ 4-subunit was expressed normally in the brains of ⁇ 2+/ ⁇ mice or ⁇ 2 ⁇ / ⁇ mice, with expression in the medial habenula (MHb) and the interpeduncular nucleus (IPN) 10 , and no upregulation elsewhere in the brain to replace the ⁇ 2-subunit (FIG. 9 A).
  • MHb medial habenula
  • IPN interpeduncular nucleus
  • Neurons of the anterior thalamus which express very high levels of ⁇ 2 (and ⁇ 4) subunit mRNAs (FIG. 9 A), were studied for an electrophysiological response to nicotine.
  • This area easily accessible in a slice preparation, responded consistently to 10 ⁇ M nicotine in wild type animals with an average inward current of 155+/ ⁇ 73 pA which was blocked by 1 ⁇ M dihydro- ⁇ -erythroidine.
  • the agonist order of the response was compatible with that seen for ⁇ 4/ ⁇ 2-containing nicotinic receptors in vitro 6 (nicotine>DMPP>cytisine) (FIG. 10 A).
  • thalamic neurons required several minutes to an hour for complete recovery of the agonist response, suggesting that receptor response is prone to desensitization. Moreover, a relatively high dose of 1 ⁇ M was required for a reproducible response, implying that nicotine does not bind to its high affinity site to activate. High affinity nicotine binding sites may therefore be nAChRs in a desensitized conformation.
  • the ⁇ 2 subunit is expressed in the ganglia of wild type animals 8-10 , but there was no apparent difference in heart rate or basal body temperature.
  • Spontaneous locomotor activity which is sensitive to high doses of nicotine and is not modified by drugs selective for the ⁇ 2/ ⁇ 4 isoform of the nAChR 16 , was not significantly different in ⁇ 2 ⁇ / ⁇ , ⁇ +/1 and ⁇ +/+mice.
  • mutants 7.4+/ ⁇ 1.4 sec
  • mutants 7.4+/ ⁇ 1.4 sec
  • Retention of an inhibitory avoidance response was assessed using the passive avoidance test, which was also chosen for its pharmacological sensitivity to nicotine administration 19,20 .
  • This test consisted of a training trial in which the mouse was placed in a well-lighted chamber of a shuttle box, and the latency to enter the adjacent dark chamber was measured. Upon entry to the dark chamber, a mild, inescapable foot shock was delivered, and vehicle or nicotine (10 ⁇ g/kg) was injected into the mouse. Twenty-four (24) hours later, retention was assessed by measuring the latency to enter the dark chamber. Time spent in the light chamber (retention latency) increased proportionally to the applied foot shock in both mutant and wild type mice.
  • nAChRs may be present in at least two pathways that interact with opposite effects to generate the behavior measured in passive avoidance. If one pathway is physiologically more active than the other, the inactive pathway will be preferentially stimulated by injection of nicotine in wild type animals, while the more active pathway will be preferentially influenced by ⁇ 2-gene inactivation.
  • mice provide a model system for studying the pharmacological effects of nicotine in the CNS, and are useful in elucidating the role of high affinity nAChRs in cognitive processes, nicotine addiction, and dementias involving deficits of the nicotinic system.
  • Table 1 Positive and negative regulatory elements in the poximal region of the 1163 bp promoter.
  • Mouse ⁇ 2 is SEQ ID NO:23
  • Sodium Channel (nt 29) is SEQ ID NO:24
  • SCG10 (nt 621) is SEQ ID NO:25
  • Synapsin I (nt 2070) is SEQ ID NO:26
  • CAML1 (nt 1535) is SEQ ID NO:27.
  • Calhindin (nt 1093) is SEQ ID NO:28
  • Neurofilament (nt 383) is SEQ ID NO. 29.
  • the activities of the wild type or mutated-promoters are normalized to the luciferase activity of the promoterless KS-Luci plasmid.
  • the activities of EE1.2-Luci are from, FIG. 3 .
  • a Neuroblastomas Fibroblasts (3T6) (SK-N-Be) EE1.2-Luci wild type 1.1 (100%) 157 (100%) EE1.2-Luci/NRSE/RE1 115.5 ⁇ 13.8 (1050%) 502 ⁇ 204 (320%) EE1.2-Luci/E-Box ND 94 ⁇ 14 (60%)
  • Antequera F. and Bird, A. (1993). Number of CpG islands and genes in human and mouse. Proc Natl Acad Sci U.S.A. 90, 11995-11999.
  • Muscle-specific expression of the acetylcholine receptor ⁇ -subunit gene requires both positive and negative interactions between myogenic factors, SpI and GBF factors. EMBO J 12,443-449.
  • Firefly luciferase gene Structure and expression in mammalian cells. Mol Cell Biol 7, 725-737.
  • the dopamine beta-hydroxylase gene promoter directs expression of E. coli lacZ to sympathetic and other neurons in adult transgenic mice. Neuron 7, 703-716.
  • Pioro E. P. and Cuello, A. C. (1990a). Distribution of nerve growth factor receptor-like immunoreactivity in the adult rat central nervous system. Effect of colchicine and correlation with the cholinergic system-I. Forebrain. Neuroscience 34, 57-87.
  • Pioro E. P. and Cuello, A. C. (1990b). Distribution of nerve growth factor receptor-like immunoreactivity in the adult rat central nervous system. Effect of colchicine and correlation with the cholinergic system-II. Brainstem, cerebellum and spinal cord. Neuroscience 34, 89-110.
  • Cyclic AMP induction of early adenovirus promoters involves sequences required for EIA trans-activation. Proc Natl Acad Sci U.S.A. 85, 7192-7196.
  • GAP-43 transgenic mice dispersed genomic sequences confer a GAP-43-like expression pattern during development and regeneration. J. Neurosci. 14,499-510

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Environmental Sciences (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Animal Husbandry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Cell Biology (AREA)
  • Neurology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
US08/358,627 1994-12-14 1994-12-14 Genomic DNA fragments containing regulatory and coding sequences for the β2-subunit of the neuronal nicotinic acetylcholine receptor and transgenic animals made using these fragments or mutated fragments Expired - Fee Related US6177242B1 (en)

Priority Applications (17)

Application Number Priority Date Filing Date Title
US08/358,627 US6177242B1 (en) 1994-12-14 1994-12-14 Genomic DNA fragments containing regulatory and coding sequences for the β2-subunit of the neuronal nicotinic acetylcholine receptor and transgenic animals made using these fragments or mutated fragments
US08/465,712 US6452066B1 (en) 1994-12-14 1995-06-06 GENOMIC DNA FRAGMENTS CONTAINING REGULATORY AND CODING SEQUENCES FOR THE β2-SUBUNIT OF THE NEURONAL NICOTINIC ACETYLCHOLINE RECEPTOR AND TRANSGENIC ANIMALS MADE USING THESE FRAGMENTS OR MUTATED FRAGMENTS
CA2165098A CA2165098C (en) 1994-12-14 1995-12-13 Genomic dna fragments containing regulatory and coding sequences for the .beta.2-subunit of the neuronal nicotinic acetylcholine receptor and transgenic animals made using these fragments or mutated fragments
AU40373/95A AU4037395A (en) 1994-12-14 1995-12-13 Genomic DNA fragments containing regulatory and coding sequences for the Beta2-subunit of the neuronal nicotinic acetylcholine receptor and transgenic animals made using these fragments or mutated fragments
JP32609495A JP4450874B2 (ja) 1994-12-14 1995-12-14 ニューロンニコチン性アセチルコリン受容体のβ２−サブユニットの調節配列及びこれをコードする配列を含むゲノムＤＮＡ断片、及びこれらの断片又は突然変異断片を用いて作製されたトランスジェニック動物
NZ280674A NZ280674A (en) 1994-12-14 1995-12-14 Promoter of beta2-subunit of neuronal nicotinic acetylcholine receptor, transgenic animals
EP95402822A EP0717105B1 (en) 1994-12-14 1995-12-14 Genomic DNA fragments of the regulating sequence for the beta2-subunit of the neuronal nicotinic acetylcholine receptor; transgenic animals containing it
DK95402822T DK0717105T3 (da) 1994-12-14 1995-12-14 Genomiske DNA-fragmenter, der indeholder den regulatoriske sekvens for beta2-underenheden af neuronnnikotinacetylcholinreceptoren; transgene dyr, der indeholder den
ES95402822T ES2238677T3 (es) 1994-12-14 1995-12-14 Fragmentos de adn genomico de la secuencia reguladora de la subunidad beta 2 del receptor nicotinico neuronal de la acetilcolina; animales transgenicos que lo contienen.
PT95402822T PT717105E (pt) 1994-12-14 1995-12-14 Fragmentos de dna genomico que codificam para a subunidade beta2 do receptor nicotinico neuronal; animais transgenicos contendo aqueles
AT95402822T ATE289628T1 (de) 1994-12-14 1995-12-14 Genomische dns fragmente der regulierenden sequenz der beta 2 untereinheit des neuronalen nikotin-acetycholin rezeptors; damit transformierte transgene tiere.
DE69534022T DE69534022T2 (de) 1994-12-14 1995-12-14 Genomische DNS Fragmente der regulierenden Sequenz der Beta 2 Untereinheit des neuronalen Nikotin-Acetycholin Rezeptors; damit transformierte transgene Tiere.
US09/349,925 US6777236B1 (en) 1994-12-14 1999-07-08 Process for producing a neuronal host cell in vitro comprising regulatory sequences of the β2-subunit of the neuronal nicotinic acetylcholine receptor
US09/552,733 US6455754B1 (en) 1994-12-14 2000-04-19 GENOMIC DNA FRAGMENTS CONTAINING REGULATORY AND CODING SEQUENCES FOR THE β2-SUBUNIT OF THE NEURONAL NICOTINIC ACETYLCHOLINE RECEPTOR AND TRANSGENIC ANIMALS MADE USING THESE FRAGMENTS OR MUTATED FRAGMENTS
US10/843,432 US7294463B2 (en) 1994-12-14 2004-05-12 Method of screening for compounds that modulate activity of a regulatory sequence of the β-2 subunit of a neuronal nicotinic acetylcholine receptor
US11/898,925 US20090013421A1 (en) 1994-12-14 2007-09-17 Genomic DNA fragments containing regulatory and coding sequences for the B2-subunit of the neuronal nicotinic acetylcholine receptor and transgenic animals made using these fragments or mutated fragments
JP2007259536A JP4468429B2 (ja) 1994-12-14 2007-10-03 ニューロンニコチン性アセチルコリン受容体のβ２−サブユニットの調節配列及びこれをコードする配列を含むゲノムＤＮＡ断片、及びこれらの断片又は突然変異断片を用いて作製されたトランスジェニック動物

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/358,627 US6177242B1 (en) 1994-12-14 1994-12-14 Genomic DNA fragments containing regulatory and coding sequences for the β2-subunit of the neuronal nicotinic acetylcholine receptor and transgenic animals made using these fragments or mutated fragments

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US08/465,712 Continuation US6452066B1 (en) 1994-12-14 1995-06-06 GENOMIC DNA FRAGMENTS CONTAINING REGULATORY AND CODING SEQUENCES FOR THE β2-SUBUNIT OF THE NEURONAL NICOTINIC ACETYLCHOLINE RECEPTOR AND TRANSGENIC ANIMALS MADE USING THESE FRAGMENTS OR MUTATED FRAGMENTS
US09/552,733 Division US6455754B1 (en) 1994-12-14 2000-04-19 GENOMIC DNA FRAGMENTS CONTAINING REGULATORY AND CODING SEQUENCES FOR THE β2-SUBUNIT OF THE NEURONAL NICOTINIC ACETYLCHOLINE RECEPTOR AND TRANSGENIC ANIMALS MADE USING THESE FRAGMENTS OR MUTATED FRAGMENTS

Publications (1)

Publication Number Publication Date
US6177242B1 true US6177242B1 (en) 2001-01-23

Family

ID=23410417

Family Applications (4)

Application Number Title Priority Date Filing Date
US08/358,627 Expired - Fee Related US6177242B1 (en) 1994-12-14 1994-12-14 Genomic DNA fragments containing regulatory and coding sequences for the β2-subunit of the neuronal nicotinic acetylcholine receptor and transgenic animals made using these fragments or mutated fragments
US08/465,712 Expired - Fee Related US6452066B1 (en) 1994-12-14 1995-06-06 GENOMIC DNA FRAGMENTS CONTAINING REGULATORY AND CODING SEQUENCES FOR THE β2-SUBUNIT OF THE NEURONAL NICOTINIC ACETYLCHOLINE RECEPTOR AND TRANSGENIC ANIMALS MADE USING THESE FRAGMENTS OR MUTATED FRAGMENTS
US09/552,733 Expired - Fee Related US6455754B1 (en) 1994-12-14 2000-04-19 GENOMIC DNA FRAGMENTS CONTAINING REGULATORY AND CODING SEQUENCES FOR THE β2-SUBUNIT OF THE NEURONAL NICOTINIC ACETYLCHOLINE RECEPTOR AND TRANSGENIC ANIMALS MADE USING THESE FRAGMENTS OR MUTATED FRAGMENTS
US11/898,925 Abandoned US20090013421A1 (en) 1994-12-14 2007-09-17 Genomic DNA fragments containing regulatory and coding sequences for the B2-subunit of the neuronal nicotinic acetylcholine receptor and transgenic animals made using these fragments or mutated fragments

Family Applications After (3)

Application Number Title Priority Date Filing Date
US08/465,712 Expired - Fee Related US6452066B1 (en) 1994-12-14 1995-06-06 GENOMIC DNA FRAGMENTS CONTAINING REGULATORY AND CODING SEQUENCES FOR THE β2-SUBUNIT OF THE NEURONAL NICOTINIC ACETYLCHOLINE RECEPTOR AND TRANSGENIC ANIMALS MADE USING THESE FRAGMENTS OR MUTATED FRAGMENTS
US09/552,733 Expired - Fee Related US6455754B1 (en) 1994-12-14 2000-04-19 GENOMIC DNA FRAGMENTS CONTAINING REGULATORY AND CODING SEQUENCES FOR THE β2-SUBUNIT OF THE NEURONAL NICOTINIC ACETYLCHOLINE RECEPTOR AND TRANSGENIC ANIMALS MADE USING THESE FRAGMENTS OR MUTATED FRAGMENTS
US11/898,925 Abandoned US20090013421A1 (en) 1994-12-14 2007-09-17 Genomic DNA fragments containing regulatory and coding sequences for the B2-subunit of the neuronal nicotinic acetylcholine receptor and transgenic animals made using these fragments or mutated fragments

Country Status (11)

Country Link
US (4) US6177242B1 (ja)
EP (1) EP0717105B1 (ja)
JP (2) JP4450874B2 (ja)
AT (1) ATE289628T1 (ja)
AU (1) AU4037395A (ja)
CA (1) CA2165098C (ja)
DE (1) DE69534022T2 (ja)
DK (1) DK0717105T3 (ja)
ES (1) ES2238677T3 (ja)
NZ (1) NZ280674A (ja)
PT (1) PT717105E (ja)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090013421A1 (en) * 1994-12-14 2009-01-08 Institut Pasteur Genomic DNA fragments containing regulatory and coding sequences for the B2-subunit of the neuronal nicotinic acetylcholine receptor and transgenic animals made using these fragments or mutated fragments
US20090136465A1 (en) * 2007-09-28 2009-05-28 Intrexon Corporation Therapeutic Gene-Switch Constructs and Bioreactors for the Expression of Biotherapeutic Molecules, and Uses Thereof

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5977144A (en) * 1992-08-31 1999-11-02 University Of Florida Methods of use and compositions for benzylidene- and cinnamylidene-anabaseines
WO1998015172A2 (en) * 1996-10-10 1998-04-16 Institut Pasteur Transgenic or mutated animal as model for a neuron deficit
DE69829402T2 (de) * 1997-10-31 2006-04-13 Affymetrix, Inc. (a Delaware Corp.), Santa Clara Expressionsprofile in adulten und fötalen organen
AU5815699A (en) * 1998-09-08 2000-03-27 Urocor, Inc. Prostate specific promoter and regulation of gene expression
US7879913B2 (en) * 2005-06-28 2011-02-01 Catholic Healthcare West Iptakalim hydrochloride for decreasing nicotine use
US7498508B2 (en) * 2006-02-24 2009-03-03 Day4 Energy, Inc. High voltage solar cell and solar cell module

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991015602A1 (en) * 1990-04-03 1991-10-17 The Salk Institute Biotechnology/Industrial Associates, Inc. Human neuronal nicotinic acetylcholine receptor compositions and methods employing same

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6177242B1 (en) * 1994-12-14 2001-01-23 Institut Pasteur Genomic DNA fragments containing regulatory and coding sequences for the β2-subunit of the neuronal nicotinic acetylcholine receptor and transgenic animals made using these fragments or mutated fragments
US6777236B1 (en) * 1994-12-14 2004-08-17 Institut Pasteur Process for producing a neuronal host cell in vitro comprising regulatory sequences of the β2-subunit of the neuronal nicotinic acetylcholine receptor

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991015602A1 (en) * 1990-04-03 1991-10-17 The Salk Institute Biotechnology/Industrial Associates, Inc. Human neuronal nicotinic acetylcholine receptor compositions and methods employing same

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Molecular Cloning. Sambrook et al., pp. 2.11-2.15, 1989. *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090013421A1 (en) * 1994-12-14 2009-01-08 Institut Pasteur Genomic DNA fragments containing regulatory and coding sequences for the B2-subunit of the neuronal nicotinic acetylcholine receptor and transgenic animals made using these fragments or mutated fragments
US20090136465A1 (en) * 2007-09-28 2009-05-28 Intrexon Corporation Therapeutic Gene-Switch Constructs and Bioreactors for the Expression of Biotherapeutic Molecules, and Uses Thereof
US9724430B2 (en) 2007-09-28 2017-08-08 Intrexon Corporation Therapeutic gene-switch constructs and bioreactors for the expression of biotherapeutic molecules, and uses thereof

Also Published As

Publication number Publication date
PT717105E (pt) 2005-05-31
JPH08242866A (ja) 1996-09-24
DK0717105T3 (da) 2005-06-20
US6452066B1 (en) 2002-09-17
NZ280674A (en) 1997-09-22
EP0717105B1 (en) 2005-02-23
AU4037395A (en) 1996-06-20
CA2165098C (en) 2010-04-13
JP2008099686A (ja) 2008-05-01
JP4468429B2 (ja) 2010-05-26
DE69534022D1 (de) 2005-03-31
JP4450874B2 (ja) 2010-04-14
US20090013421A1 (en) 2009-01-08
EP0717105A2 (en) 1996-06-19
US6455754B1 (en) 2002-09-24
CA2165098A1 (en) 1996-06-15
ATE289628T1 (de) 2005-03-15
ES2238677T3 (es) 2005-09-01
EP0717105A3 (en) 1999-04-07
DE69534022T2 (de) 2006-04-27

Similar Documents

Publication Publication Date Title
Zerucha et al. A highly conserved enhancer in the Dlx5/Dlx6Intergenic region is the site of cross-regulatory interactions betweenDlx genes in the embryonic forebrain
Gainetdinov et al. Muscarinic supersensitivity and impaired receptor desensitization in G protein–coupled receptor kinase 5–deficient mice
Casademunt et al. The zinc finger protein NRIF interacts with the neurotrophin receptor p75NTR and participates in programmed cell death
US20090013421A1 (en) Genomic DNA fragments containing regulatory and coding sequences for the B2-subunit of the neuronal nicotinic acetylcholine receptor and transgenic animals made using these fragments or mutated fragments
US20080168571A1 (en) Transgenic animal
JPH10503091A (ja) アセチルコリン作動性イオンチャネル受容体サブユニットのクローニングと発現
Wehner et al. The use of null mutant mice to study complex learning and memory processes
US6777236B1 (en) Process for producing a neuronal host cell in vitro comprising regulatory sequences of the β2-subunit of the neuronal nicotinic acetylcholine receptor
JP2003513645A (ja) メラノコルチン−３レセプター欠失細胞、非ヒトトランスジェニック動物及び体重を調節する化合物の選択方法
US20070011757A1 (en) Transgenic rodents as animal models for modulation of B1 bradykinin receptor protein
US6753456B2 (en) Point mutant mice with hypersensitive alpha 4 nicotinic receptors: dopaminergic pathology and increased anxiety
JP2007105046A (ja) Ｎ型カルシウムチャネルノックアウト動物を利用する物質の作用の測定方法
JP2005503143A (ja) Ｋｖベータ１．１サブユニットの非機能性Ｎ末端を含んでいるノックイントランスジェニック哺乳動物
CA2559880A1 (en) Knock-out animal for taar1 function
Minoguchi et al. Studies on the cell-type specific expression of RBP-L, a RBP-J family member, by replacement insertion of β-galactosidase
US7820876B2 (en) Mouse mutant for expression of the alpha6 subunit of the nicotinic acetylcholine receptor
EP1116790A1 (en) Murine models characterized by conditional mutation of SMN gene - use for study of spinal muscular atrophy and other neurodegenerative diseases and muscular myopathies
Kim et al. The promoter of brain-specific angiogenesis inhibitor 1-associated protein 4 drives developmentally targeted transgene expression mainly in adult cerebral cortex and hippocampus
JP2000510001A (ja) 分断されたｎｐｙ ｙ１受容体遺伝子を有するトランスジェニック動物
US7445904B2 (en) Cysteine string protein and its role in neurodegenerative diseases
JP2003525596A (ja) メラノコルチン−４受容体欠損細胞、非ヒトトランスジェニック動物および体重調節化合物の選択方法
US20050014834A1 (en) Selective anesthetic agents and methods of identifying the same
Rowan et al. Genetic analysis of ChxlO and BMP4 in the retina using a novel multi-reporter BAC transgenic mouse

Legal Events

Date Code Title Description
AS Assignment

Owner name: INSTITUT PASTEUR, FRANCE

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:CHANGEUX, JEAN-PIERRE;PICCIOTTO, MARINA;BESSIS, ALAIN;REEL/FRAME:007373/0965

Effective date: 19950123

CC Certificate of correction
FPAY Fee payment

Year of fee payment: 4

REMI Maintenance fee reminder mailed
FPAY Fee payment

Year of fee payment: 8

SULP Surcharge for late payment

Year of fee payment: 7

REMI Maintenance fee reminder mailed
LAPS Lapse for failure to pay maintenance fees
STCH Information on status: patent discontinuation

Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362

FP Lapsed due to failure to pay maintenance fee

Effective date: 20130123